Type 2 diabetes (T2D) is a chronic and progressive metabolic disorder characterized by the development of insulin resistance and the gradual deterioration of pancreatic β-cell function over time. The main therapeutic goals when dealing with T2D involve not only attaining optimal control over blood sugar levels but also addressing the potential cardiovascular and metabolic risks associated with the disease, including the often prevalent condition of obesity in affected individuals [1,2]. While conventional treatment strategies such as metformin, sulfonylureas, and insulin have demonstrated their efficacy in lowering blood glucose levels, they frequently fall short when it comes to tackling other crucial facets of the illness, such as weight management and the broader spectrum of metabolic dysfunctions that contribute to the advancement of T2D [3]. In recent times, a new avenue has opened up for the management of T2D through the introduction of incretin-based therapies, which present a promising alternative focusing on both controlling blood sugar levels and managing body weight simultaneously. GLP-1 (Glucagon-Like Peptide-1) receptor agonists, exemplified by medications like semaglutide and liraglutide, have exhibited exceptional results in reducing HbA1c levels and fostering weight loss, predominantly by enhancing the secretion of insulin, suppressing the release of glucagon, and increasing feelings of satiety [4-7]. Despite the marked success of GLP-1 receptor agonists, the potential of GIP (Glucose-dependent Insulinotropic Peptide), another key incretin hormone, remains largely untapped within the realm of T2D treatment. Recent research ventures exploring the concept of dual incretin therapy, incorporating combinations of GLP-1 and GIP receptor agonists or GLP-1 with DPP-4 (Dipeptidyl Peptidase-4) inhibitors, have hinted at a synergistic effect in terms of both regulating blood sugar levels and addressing body weight concerns [8]. This dual therapeutic strategy has the potential to offer a more holistic approach for individuals dealing with T2D, particularly those wrestling with obesity and compromised metabolic well-being [9, 10]. This study aims to examine the efficacy, safety, and tolerability of dual incretin therapy in T2D, comparing its outcomes with traditional monotherapies. The goal is to evaluate whether dual incretin therapy can provide a more holistic and effective treatment option for managing both hyperglycemia and obesity, thus improving overall patient outcomes.

Study Design

This study is a multicenter, randomized, open-label, phase 3 clinical trial designed to evaluate the efficacy and safety of dual incretin therapy in patients with inadequately controlled type 2 diabetes (T2D). Conducted across five academic centers from January 2023 to June 2024, the trial adhered to strict ethical standards. The protocol received approval from the Institutional Review Board (IRB) at each participating center, and all participants provided written informed consent before enrolment.

Participants

Inclusion criteria were

• Age 40-75 years,
• Diagnosis of T2D for at least 1 year,
• HbA1c levels between 7.5% and 10.5% despite stable doses of oral antidiabetic drugs (OADs),
• BMI between 25 and 40 kg/m².

Exclusion criteria included

• Severe renal or hepatic impairment,
• History of pancreatitis or severe gastrointestinal disease,
• Pregnancy or breastfeeding.

Interventions

Participants were randomly assigned to one of three treatment groups for a 24-week period:

• Group 1: Dual Incretin Therapy, consisting of a GLP-1 receptor agonist (semaglutide) combined with a GIP receptor agonist (tirzepatide).
• Group 2: Monotherapy with a GLP-1 receptor agonist (semaglutide) alone.
• Group 3: Monotherapy with a DPP-4 inhibitor (sitagliptin) alone.

All participants continued their baseline regimen of metformin throughout the study.

Outcome Measures

Primary outcomes:

• Change in HbA1c levels from baseline to 24 weeks.
• Change in body weight from baseline to 24 weeks.

Secondary outcomes:

• Incidence of adverse events (AEs).
• Changes in lipid profiles and blood pressure.

Statistical Analysis

Data were analyzed using one-way Analysis of Variance (ANOVA) for between-group comparisons, with a significance level set at p < 0.05. To account for missing data, the Last Observation Carried Forward (LOCF) method was employed. A post-hoc analysis was also conducted to evaluate subgroup differences based on baseline body mass index (BMI) and age.

Baseline Characteristics

A total of 300 participants were enrolled in the study, with 100 patients in each treatment group. The baseline characteristics of the participants were similar across the three groups, as shown in (Table 1).

Table 1: Baseline Characteristics of Participants by Treatment Group (n =300).

Glycemic Control

After 24 weeks of treatment, the group receiving dual incretin therapy (GLP-1 + GIP) demonstrated a significantly greater reduction in HbA1c levels compared to the monotherapy groups. The mean HbA1c reduction in the dual therapy group was 2.1%, which was notably higher than the reductions observed in the GLP-1 monotherapy group (1.5%) and the DPP-4 monotherapy group (1.0%) (Table 2).

Table 2: HbA1c Reduction in T2D Patients Treated with Dual Incretin Therapy vs. Monotherapies (Baseline to 24-Week Endpoint).

Weight Management

The dual incretin therapy group also achieved superior weight loss. On average, participants in this group lost 11.2 kg, compared to 6.8 kg in the GLP-1 monotherapy group and 4.3 kg in the DPP-4 monotherapy group (Table 3).

Table 3: Weight Loss in T2D Patients Treated with Dual Incretin Therapy vs. Monotherapies (Baseline to 24-Week Endpoint).

Safety and Tolerability

The safety profiles of all treatment groups were generally similar, with gastrointestinal adverse events, such as nausea and vomiting, being the most commonly reported, particularly in the GLP-1 and dual therapy groups. However, the incidence of severe adverse events was low across all groups, with no cases of pancreatitis or other serious complications observed.

Subgroup Analysis

Post-hoc subgroup analyses revealed that the benefits of dual incretin therapy were most pronounced in participants with a baseline body mass index (BMI) greater than 30 kg/m². In this subgroup, both HbA1c reductions and weight loss were notably more substantial compared to participants with a lower BMI.

Summary of Findings

This study provides compelling evidence that dual incretin therapy by combining the benefits of GLP-1 (Glucagon-Like Peptide-1) and GIP (Glucose-Dependent Insulinotropic Peptide) receptor agonists represents a significant advancement in the management of both hyperglycemia and obesity in individuals with type 2 diabetes (T2D). The results indicate that this combination therapy leads to a significantly greater reduction in HbA1c levels and more substantial weight loss compared to the use of monotherapies (GLP-1 or DPP-4 inhibitors), highlighting the potential of dual incretin therapies to address two of the most challenging aspects of T2D: poor glycemic control and obesity [7,11]. The dual incretin approach offers promising therapeutic outcomes, particularly for individuals with T2D who face the dual burden of elevated blood sugar and excess body weight. By enhancing insulin secretion and promoting satiety, while also inhibiting glucagon release, this therapy addresses the pathophysiological underpinnings of T2D in a more holistic manner [3]. Moreover, the results suggest that this combined approach may not only be more effective in lowering blood sugar levels but also in fostering weight reduction, which is a critical factor in managing T2D and reducing cardiovascular risks [12]. These findings underscore the potential of dual incretin therapy as a breakthrough in T2D management, offering a comprehensive solution for patients struggling with both hyperglycemia and obesity. By targeting these intertwined issues, dual incretin therapy may pave the way for improved patient outcomes and enhanced long-term management of this chronic metabolic condition, with a focus on reducing the risks of cardiovascular events and improving quality of life [1, 11].

Mechanism of Action

In the realm of dual incretin therapy, the synergistic interplay between GLP-1 (Glucagon-Like Peptide-1) and GIP (Glucose-Dependent Insulinotropic Peptide) forms a powerful combination that triggers a cascade of beneficial physiological effects. This cooperative action significantly enhances insulin secretion, improves insulin sensitivity, and promotes satiety, all of which are crucial for the effective management of Type 2 Diabetes (T2D) [9]. The combined action of these incretins also helps counteract the weight gain often associated with conventional diabetes medications, addressing one of the most challenging aspects of T2D management [5]. The ability of dual incretin therapy to influence multiple metabolic pathways such as insulin secretion, glucose homeostasis, and appetite regulation offers a comprehensive approach to treating T2D. By harnessing the individual strengths of GLP-1 and GIP, this novel therapeutic strategy holds significant promise for improving both glycemic control and weight management in patients who struggle with the dual burden of elevated blood glucose and obesity [13]. These mechanisms align with the growing body of evidence suggesting that dual incretin therapy could revolutionize T2D treatment by providing a holistic, multifaceted solution to a complex metabolic disorder [14].

Clinical Implications

The findings from this study strongly support the use of dual incretin therapy as a promising new treatment approach for individuals with Type 2 Diabetes (T2D), especially for those with concurrent obesity or for patients who have not achieved sufficient glycemic control with monotherapies. By targeting both hyperglycemia and obesity, dual incretin therapy addresses two key components of the disease, offering a more comprehensive treatment strategy. Additionally, the favorable safety profile observed in this study further enhances the potential for widespread adoption of dual incretin therapy, especially considering the growing need for more effective and well-tolerated treatments for T2D. This approach may help optimize patient outcomes by not only improving glycemic control but also reducing cardiovascular and metabolic risks associated with obesity and insulin resistance.

Limitations

While this study provides promising results, certain limitations must be acknowledged. The open-label design introduces potential bias, and the relatively short study duration of 24 weeks limits our ability to assess the long-term sustainability of the treatment’s effects. Furthermore, the study does not evaluate the broader impact of dual incretin therapy on key outcomes such as cardiovascular and renal health, which are critical for T2D patients. Future research, particularly long-term studies, will be essential to fully understand the comprehensive benefits of dual incretin therapy, including its effects on hard endpoints such as heart disease, kidney function, and overall mortality in individuals with T2D. These studies will help confirm whether the promising results observed in this trial can translate into sustained clinical benefits over time.

Dual incretin therapy, which combines GLP-1 and GIP receptor agonists, offers superior glycemic control and more significant weight loss compared to traditional monotherapies in patients with type 2 diabetes. This innovative treatment approach holds particular promise for individuals who struggle with both obesity and insufficient glycemic control, addressing two of the most pressing challenges in managing the condition. While the results are compelling, further long-term studies are necessary to fully understand the therapy's long-term benefits, including its safety profile and impact on cardiovascular and renal outcomes. As the evidence base grows, dual incretin therapy could become a cornerstone in the management of type 2 diabetes, providing a more holistic solution for patients facing the complex interplay between elevated blood sugar and obesity.

1. American Diabetes Association. Standards of medical care in diabetes 2023. Diabetes Care. 2023; 46: 1-70.
2. Feldman H, Sayed NA, Freeman R, McCoy RG, Moverley JA, Oser SM, et al. Standards of medical care in diabetes—2022 abridged for primary care providers. Clinical Diabetes. 2022; 40: 10-38.
3. Draznin B. Management of type 2 diabetes: Focus on new treatments and emerging therapies. J Clin Endocrinol Metab. 2022; 107: 512-523.
4. Kupai K, Varkonyi T, Torok S, Gati V, Czimmerer Z, Puskas LG, et al. Recent progress in the diagnosis and management of type 2 diabetes mellitus in the era of COVID-19 and single cell multi-omics technologies. Life. 2022 Aug 8; 12: 1205.
5. Mannucci E, et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: Mechanisms and clinical outcomes. Diabetes Obes Metab. 2023; 25: 1412-1421.
6. Kupnicka P, Krol M, Zychowska J, Lagowski R, Prajwos E, Surowka A, et al. GLP-1 Receptor Agonists: A Promising Therapy for Modern Lifestyle Diseases with Unforeseen Challenges. Pharmaceuticals. 2024; 17: 1470.
7. Gonzalez T, et al. Synergistic effects of dual incretin therapy in type 2 diabetes: A meta-analysis. J Diabetes Res. 2023; 2023: 1058-1065.
8. Lisco G, De Tullio A, Iovino M, Disoteo O, Guastamacchia E, Giagulli VA, et al. Dopamine in the regulation of glucose homeostasis, pathogenesis of type 2 diabetes, and chronic conditions of impaired dopamine activity/metabolism: Implication for pathophysiological and therapeutic purposes. Biomedicines. 2023; 11: 2993.
9. Albiges L, et al. Efficacy of tirzepatide in type 2 diabetes: The SURPASS program. Diabetes Care. 2023; 46: 43-52.
10. Min T, Bain SC. The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: the SURPASS clinical trials. Diabetes Therapy. 2021; 12: 143-157.
11. Albiges L, et al. Dual incretin therapy in type 2 diabetes: Emerging evidence and potential. J Diabetes Complications. 2023; 37: 107-118.
12. Mannucci E, et al. Effectiveness of dual incretin therapy in type 2 diabetes management. Diabet Med. 2023; 40: 258-264.
13. American Diabetes Association. Standards of medical care in diabetes—2023. Diabetes Care. 2023; 46: S1-S131.
14. Albiges L, et al. Dual incretin therapy in type 2 diabetes: Emerging evidence and potential. J Diabetes Complications. 2023; 37: 107-118.